- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Gaithersburg Today
By the People, for the People
GeneDx Holdings Corp. $WGS Stake Reduced by Fred Alger Management LLC
Institutional investor cuts position in genomics company by over 50%
Mar. 16, 2026 at 10:18am
Got story updates? Submit your updates here. ›
Fred Alger Management LLC, an institutional investor, reduced its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 56.5% during the third quarter, according to a recent SEC filing. The firm now owns 357,302 shares of the company's stock, down from 820,523 shares previously.
Why it matters
GeneDx is a leading provider of genetic and genomic testing services, so changes in institutional ownership of the company's stock can signal shifts in investor sentiment and outlook for the business.
The details
According to the 13F filing, Fred Alger Management LLC sold 463,221 shares of GeneDx stock during the third quarter, reducing its position by over 56%. The firm now owns approximately 1.24% of GeneDx's outstanding shares, valued at $38.5 million.
- The stake reduction occurred during the third quarter of the year.
The players
Fred Alger Management LLC
An institutional investment management firm that has reduced its position in GeneDx Holdings Corp.
GeneDx Holdings Corp.
A clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders.
The takeaway
The significant reduction in Fred Alger Management's stake in GeneDx could signal broader investor concerns about the company's outlook or performance, though more information would be needed to determine the specific reasons behind the portfolio change.
